Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895891 | 0.86 | NOTUM (0.54) | GRM5PKMMEN1GAAKMT2A | |
| SCHEMBL2895023 | 0.84 | GRM5 (0.44) | GRM5PKMMEN1GAAKMT2A | |
| SCHEMBL5739257 | 0.82 | GRM5 (0.42) | GRM5PKMMEN1GAAKMT2A | |
| SCHEMBL2897304 | 0.82 | NOTUM (0.50) | GRM5PKMMEN1GAAKMT2A | |
| SCHEMBL3955492 | 0.82 | GRM5 (0.42) | GRM5PKMMEN1GAAKMT2A | |
| SCHEMBL5740467 | 0.81 | DRD4 (0.41) | GAAALDH1A1LMNA | |
| SCHEMBL13892315 | 0.80 | KDM4E (0.49) | GRM5PKMMEN1KMT2ANPC1 | |
| SCHEMBL13892294 | 0.80 | NOTUM (0.48) | GRM5KMT2ANPC1ALDH1A1LMNA | |
| SCHEMBL4407303 | 0.80 | HPGD (0.57) | GRM5PKMNPC1ALDH1A1LMNA | |
| SCHEMBL2895781 | 0.79 | PKM (0.39) | GRM5PKMMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273805-A1 | SULPHIDE BRIDGED DERIVATIVES AS MODULATORS OF MGLUR5 733 | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273805-A1 | SULPHIDE BRIDGED DERIVATIVES AS MODULATORS OF MGLUR5 733 | GRM5, GRM3, GRIK5 | GRM5 1/4885PKM 2640/4885MEN1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.